Clive Dix speaks to Proactive London’s Andrew Scott following the news they’ve raised around £6.6mln to strengthen its balance sheet amid ongoing licensing discussions for its early-stage drug candidates.
This website uses 'cookies' to give you the best most relevant experience. To continue you have to agree to our use of cookies policy and how and why we use cookies.
You can change which cookies are set at any time and find out more about them by reading our privacy policy.